nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

01.06.2015 | Original Article

Identifying hepatocellular carcinoma-related genes and pathways by system biology analysis

verfasst von: P. Wang, L. Ouyang, L. Zheng, Z. Wang

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Previous researches have been focused on revealing the functions of each individual gene and/or pathway in the initiation, progression and maintenance of hepatocellular carcinoma (HCC). However, the mechanistic relationships among different genes and/or pathways are largely unknown.

Aims

In this study, we tended to uncover the potential molecular networks and critical genes which play important roles in HCC progression.

Methods

The transcriptional profiles from normal and HCC patient samples were analyzed and compared using bioinformatic methods, including differentially expressed gene (DEG) analysis, hierarchical clustering, construction of protein–protein interaction (PPI) network and GO-Elite analysis.

Results

Initially, the normal and HCC sample data were processed and 679 most dramatic DEGs were identified. The PPI network analysis indicates the significance of multiple biological processes as well as signaling pathways in affecting liver function and HCC progression. In addition, hierarchical clustering analysis showed the most significant modules and identified the relationship between different genes, and some important genes such as FOS, IGF1, ADH4, ITGA2 and LEF1 were found to be hubs which master each individual module.

Conclusion

Our study greatly improves the understanding of the HCC development in a systematic manner and provides the potential clue for exploiting drugs which might target the most significant genes and/or signaling pathways.

Nur mit Berechtigung zugänglich

Adamek A, Kasprzak A, Mikos H et al (2013) The insulin-like growth factor-1 and expression of its binding protein-3 in chronic hepatitis C and hepatocellular carcinoma. Oncol Rep 30(3):1337–1345PubMed

American Cancer Society (2013) Cancer Statistics 2013, 1–59

Asselah T, Bieche I, Laurendeau I et al (2005) Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129:2064–2075CrossRefPubMed

Bevoglu D, Imbeaud S, Maurhofer O et al (2013) Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 58:229–238CrossRef

Boyault S, Rickman DS, de Reynies A et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42–52CrossRefPubMed

Chaudhary P, Sharma R, Sahu M et al (2013) 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway. J Biol Chem 288:20532–20546CrossRefPubMedCentralPubMed

Coutts AS, La Thangue N (2006) The p53 response during DNA damage: impact of transcriptional cofactors. BioChem Soc Symp 73:181–189PubMed

Drozoy I, Bornschein J, Wex T et al (2012) Functional and topological properties in hepatocellular carcinoma transcriptome. PLoS ONE 7:e35510CrossRef

Dihal AA, van der Woude H et al (2008) Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics 8(1):45–61CrossRefPubMed

10.

Gentleman RC, Carey VJ, Huber W, Hahne F (2009) Genefilter: methods for filtering genes from microarray experiments. R Package Version 1.24.2., Bioconductor 2.6. http://bioc.ism.ac.jp/2.6/bioc/html/genefilter.html. Accessed 20 Aug 2013

11.

Han YC, Zheng ZL et al (2013) Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1. J Pathol 230(2):184–193CrossRefPubMedCentralPubMed

12.

Halaby MJ, Yang DQ (2007) p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene 395:1–7CrossRefPubMed

13.

Hayashi M, Nomoto S et al (2014) Identification of the collagen type 1 alpha 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer 14(1):108CrossRefPubMedCentralPubMed

14.

Huang C, Wang Y et al (2013) Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma. J Proteome Res 12(4):1838–1846CrossRefPubMed

15.

Jiang J, Gusev Y, Aderca I et al (2008) Association of Micro RNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14:419–427CrossRefPubMedCentralPubMed

16.

Jiang JG, Chen CL, Card JW et al (2005) Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65:4707–4715CrossRefPubMed

17.

Kao YH, Chen CL, Jawan B et al (2010) Upregulation of hepatoma-derived growth factor is involved in murine hepatic fibrogenesis. J Hepatol 52(1):96–105CrossRefPubMed

18.

Komatsu Y, Waku T, Iwasaki N et al (2012) Global analysis of DNA methylation in early-stage liver fibrosis. BMC Med Genomics 5:5CrossRefPubMedCentralPubMed

19.

Lai KK, Shang S, Lohia N et al (2011) Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 7:e1002147CrossRefPubMedCentralPubMed

20.

Lee SY, Kim JW et al (2008) Microtubule-associated protein 1B light chain (MAP1B-LC1) negatively regulates the activity of tumor suppressor p53 in neuroblastoma cells. FEBS Lett 582(19):2826–2832CrossRefPubMed

21.

Levine AJ, Puzio-Kuter AM (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340–1344CrossRefPubMed

22.

Matsuo M, Terai K et al (2012) Designation of enzyme activity of glycine-N-acyltransferase family genes and depression of glycine-N-acyltransferase in human hepatocellular carcinoma. Biochem Biophys Res Commun 420(4):901–906CrossRefPubMed

23.

Mazurek S (2011) Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43:969–980CrossRefPubMed

24.

Midorikawa Y, Makuuchi M, Tang W et al (2007) Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol 13:1487–1492CrossRefPubMedCentralPubMed

25.

Oh JH, Kim YB, Gurnani P et al (2008) Biomarker selection and sample prediction for multi-category disease on MALDI-TOF data. Bioinformatics 24:1812–1818CrossRefPubMed

26.

Pei Y, Zhang T, Renault V et al (2009) An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochim Biophys Sin (Shanghai) 41:1–15CrossRef

27.

Rehem RN, El-Shikh WM (2011) Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology 58:949–954PubMed

28.

Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds) Bioinformatics and computational biology solutions using R and bioconductor. Springer, New York, pp 397–420

29.

Sun S, Lee NP, Poon RT et al (2007) Oncoproteomics of hepatocellular carcinoma: from cancer markers’ discovery to functional pathways. Liver Int 27:1021–1038CrossRefPubMed

30.

Szklarczyk D, Franceschini A, Kuhn M et al (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39:D561–D568CrossRefPubMedCentralPubMed

31.

Tanaka S, Moqushi K, Yasen M et al (2011) Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology 54:1273–1281CrossRefPubMed

32.

Taniquchi K, Yamada T, Sasaki Y et al (2010) Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma. BMC Cancer 10:530CrossRef

33.

Tavazoie S, Huqhes JD, Campbell MJ et al (1999) Systematic determination of genetic network architecture. Nat Genet 22:281–285CrossRefPubMed

34.

Troyanskaya O, Cantor M, Sherlock G et al (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17:520–525CrossRefPubMed

35.

Wang L, Huang J, Jiang M (2010) RRM2 computational phosphoprotein network construction and analysis between no-tumor hepatitis/cirrhotic liver tissues and human hepatocellular carcinoma (HCC). Cell Physiol Biochem 26:303–310CrossRefPubMed

36.

Wang W, Sun Q, Wu Z et al (2013) Mitochondrial dysfunction-related genes in hepatocellular carcinoma. Front Biosci (Landmark Ed) 18:1141–1149CrossRef

37.

Wang Z, Jiang Y, Guan D et al (2013) Critical roles of p53 in epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma cells. PLoS ONE 8:e72486CrossRefPubMedCentralPubMed

38.

Wei RR, Zhang MY, Rao HL et al (2012) Identification of ADH4 as a novel and potential prognostic marker in hepatocellular carcinoma. Med Oncol 29:2737–2743CrossRefPubMed

39.

Wu Z, Irizarry RA, Gentleman R et al (2004) A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99:909–917CrossRef

40.

Wurmbach E, Chen YB, Khitroy G et al (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45:938–947CrossRefPubMed

41.

Yang W, Xia Y, Ji H et al (2011) Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480:118–122CrossRefPubMedCentralPubMed

42.

Zambon AC, Gai S, Ho I et al (2012) GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics 28:2209–2210CrossRefPubMedCentralPubMed

43.

Zhang X, Lu X, Shi Q et al (2006) Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics 7:197CrossRefPubMedCentralPubMed

44.

Zhang Y, Wang S, Li D et al (2011) A systems biology-based classifier for hepatocellular carcinoma diagnosis. PLoS ONE 6:e22426CrossRefPubMedCentralPubMed

45.

Zhou HJ, Liu YK, Li Z et al (2007) Analysing protein–protein interaction networks of human liver cancer cell lines with diverse metastasis potential. J Cancer Res Clin Oncol 133:663–672CrossRefPubMed

46.

Zhou SF, Wang B, Yang LP et al (2010) Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 42:268–354CrossRefPubMed

Titel: Identifying hepatocellular carcinoma-related genes and pathways by system biology analysis
verfasst von: P. Wang
L. Ouyang
L. Zheng
Z. Wang
Publikationsdatum: 01.06.2015
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 2/2015
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-014-1119-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Impact of intracameral cefuroxime on the incidence of postoperative endophthalmitis following cataract surgery in Ireland

Surgery of the femur in HIV positive patients: a retrospective review from 2005 to 2011

Venous thromboembolism prophylaxis guideline compliance: a pilot study of augmented medication charts

Urinary angiotensinogen as a potential biomarker of intrarenal renin–angiotensin system activity in Chinese chronic kidney disease patients

Concussion knowledge and management practices among coaches and medical staff in Irish professional rugby teams

Open versus laparoscopic abdominal rectopexy: an examination of early postoperative outcomes